drugset / Trial / NCT00892710

Trial of Poor Performance Status Patients (ToPPS)

NCT00892710 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.

Timeline

Start
2009-06
Primary completion
2014-07
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Subject Carboplatin Small molecule 5 unknown Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous